AXWAY
20.4.2016 08:01:53 CEST | Business Wire | Press release
Axway , a market leader in digital business enablement, is pleased to be the technology partner of Les Echos, the leading business and financial daily media in France, in support of its premier Hackathon event, “Hackapress des Echos ” in Paris, France. In less than 48 hours, 50 developers and designers in eight teams will compete to deliver the most innovative code that will better enable Les Echos’ use of data to enrich editorial work. With a successful track record enabling hackathons and other digital transformation initiatives, Axway will provide the digital platform for the event.
Today’s digital economy forces organizations to reinvent traditional business with innovative services. Many of them take advantage of hackathons to find new creative ways to provide better customer experiences and to build a digital culture between teams.
With the objective to reenergize the way Les Echos journalists work with their content in today’s digital age, “Hackapress des Echos” will help to forge connections between student developers, designers, and startups. Axway commits to innovation by supporting partners’ hackathon initiatives with API Management , providing technological means for hackathoners to utilize data intelligently to engage with their digital ecosystem, harvest information from data sources, and develop new methods for their projects.
“We are looking forward to seeing what creative and original projects the teams are able to develop, and this is exciting,” said Jeanine Banks, executive vice president, global products and solutions. “We believe that the future of digital business relies not only on APIs and other digital transformation technologies, but also the young minds of those who innovate.”
To stimulate and assist participants in preparing their projects, representatives from Les Echos (including journalists) will be present as mentors, observers, or participants. Teams will then present their projects at the conclusion of the event. The jury will be composed of Francis Morel, Chairman of Groupe Les Echos; Henri Gibier, Director of Editorials Developments Groupe Les Echos; Digital Village (start-ups and individuals freelancers specialize in digital); and Raise investment company.
The prize for winners, sponsored by Axway, will be presented by Francis Morel, and Bruno Patino (Director of the Journalism School of Sciences Po).
WHAT: Hackapress des Echos
WHEN: April 28-29, 2016
WHERE: Sciences Po Paris, 27 Rue Saint-Guillaume, 75007 Paris
PARTNERS OF HACKATHON DES ECHOS: Axway, Sciences Po, Digital Village, Digital Campus, Paris City Hall and Raise Endowment Fund
WHO: Students, freelancers, startups and observing outsiders
REGISTRATION: All attendees must register, here .
Follow Axway’s news on Twitter: @Axway #APIFirst #DigitalBusiness
About Axway
Axway (Euronext:AXW.PA) empowers more than 11,000 customers worldwide to collaborate smarter, innovate faster and engage better with their partners, developers and customers. From integration technology that securely connects people, processes and things to an engagement platform that enables API management, identity management, mobile app development and analytics, Axway solutions are enabling digital business. Axway is registered in France with headquarters in the United States. More information is available at: www.axway.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160419006912/en/
Contact:
Media
Neil Desai, 415-856-5150
Blanc & Otus
neil.desai@blancandotus.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom